Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-04-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2021年度独立董事述职报告（蒋昌建已离任）
Board/Management Information Classification · 95% confidence The document is titled '2021 年度独立董事述职报告' which translates to '2021 Annual Independent Director's Work Report'. It details the independent director's activities, attendance at board meetings, opinions on various board resolutions, committee work, investigations, investor protection efforts, and training during the 2021 fiscal year. The content focuses on the independent director's duties and oversight rather than presenting financial statements or audit results. It is a report on management and governance activities by an independent director rather than a full annual report, audit report, or regulatory filing. This aligns best with the category 'Board/Management Information (MANG)', which covers announcements of changes or reports related to the company's board or senior management. The document is over 5,000 characters and contains substantive content about board activities, not just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2022-04-22 Chinese
2021年度独立董事述职报告（吴育辉）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2021" from Shenzhen BGI Genomics Co., Ltd. It details the independent director's attendance at board meetings, opinions on various board resolutions, committee work, investigations, investor protection efforts, and training during the 2021 fiscal year. The content is a detailed report on the independent director's duties and activities over the year, which is a form of management or board-related reporting. It is not an annual report, audit report, earnings release, or any other financial statement. It is also not a brief announcement or a proxy solicitation. The document is a comprehensive report on board/management information, specifically the independent director's report on their duties and opinions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (6211 characters) supports it being a full report rather than a brief announcement.
2022-04-22 Chinese
关于举行2021年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding the 2021 annual performance explanation meeting (业绩说明会) for Shenzhen BGI Genomics Co., Ltd. It references that the 2021 Annual Report has already been disclosed on April 23, 2022, and invites investors to participate in an online meeting to discuss the company's performance. The document does not contain the actual annual report or financial data but is an invitation and notice for an investor presentation event. Therefore, it fits the category of Investor Presentation (IP). The document length is short and it is not a report publication announcement or certification. Hence, the classification is Investor Presentation (IP) with high confidence.
2022-04-22 Chinese
关于2021年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2021 annual profit distribution plan of Shenzhen BGI Genomics Co., Ltd. It details the proposed dividend payout, legal compliance, and approvals by the board, independent directors, and supervisory board. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. It is a formal announcement of a dividend plan rather than the dividend payment notice itself or a full annual report. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), as it announces the dividend amount and related details for shareholders.
2022-04-22 Chinese
2021年年度报告
Annual Report Classification · 100% confidence The document is titled "深圳华大基因股份有限公司 2021 年年度报告全文" which translates to "BGI Genomics Co., Ltd. 2021 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, management discussion and analysis, governance, environmental and social responsibility, financial reports, and audit reports. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. The presence of signatures from company officers and auditors further confirms this is the full annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-22 Chinese
2021年年度财务报告
Annual Report Classification · 100% confidence The document is titled "深圳华大基因股份有限公司 2021 年年度财务报告" which translates to "Shenzhen BGI Genomics Co., Ltd. 2021 Annual Financial Report." It contains detailed consolidated and parent company financial statements including balance sheets, profit and loss statements, cash flow statements, and changes in equity for the fiscal year ending December 31, 2021. The length is substantial (15,000 characters) and includes comprehensive financial data and analysis for the full fiscal year 2021. This matches the definition of an Annual Report (10-K) which covers company activity and full financial performance for the year. There is no indication that this is merely an announcement or a certification, nor is it a quarterly or interim report. Therefore, the document is classified as an Annual Report (10-K). FY 2021
2022-04-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.